Caricamento...
Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates
The development of a new generation of coagulation factors with improved pharmacokinetic profile will change the paradigm of treatment of persons with hemophilia (PWH). The standard treatment in PWH is represented by regular long-term prophylaxis that, given intravenously twice or thrice weekly, is...
Salvato in:
| Pubblicato in: | J Clin Med |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5406771/ https://ncbi.nlm.nih.gov/pubmed/28350322 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm6040039 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|